People
Industry experts say a vaccine against the SARS-CoV-2 virus will either be ready this fall, at the end of the year or 18 months from now, depending on the vaccine and how they define “ready.”
The round was led by Seroba Life Sciences, a European venture capital firm in Dublin.
The company announced its Covance drug development business was launching COVID-19 Clinical Trial Connect in the U.S. to help people find information on taking part in clinical trials related to COVID-19.
Of the Phase III trial, Fauci indicated that the majority of trial participants will be between the ages of 18 and 55, but will include elderly Americans that are most at risk of serious illness from COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 2, 2020.
U.S. Food and Drug Administration (FDA) Commissioner Stephen M. Hahn recently gave a speech to the Alliance for a Stronger FDA. In it, he suggested that some of the changes forced on the agency by the COVID-19 pandemic are likely to become permanent.
Cell and gene therapies must scale up on an industrial level if they are to deliver their full potential to patients worldwide, according to speakers at the International Society of Cell Therapy meeting, ISCT Paris 2020 Virtual, May 29.
The San Francisco Business Times recently highlighted four women who are making strides in addressing the novel coronavirus in its “Influential Women of 2020” series.
After four years as head of Sanofi’s vaccines division, David Loew is departing the pharma giant to take on a new role – chief executive officer of Paris-based Ipsen, effective July 1.
Numerous biopharmaceutical companies and researchers are presenting research and clinical trial results, and many have been announcing their plans for several weeks.
PRESS RELEASES